

# METabolic EXplorer: turnover for first-half 2010

Clermont-Ferrand, 15 July 2010 – METabolic Explorer, a green chemistry company that specializes in bioprocesses for the production of chemical compounds used in a wide range of everyday products (paints, solvents, animal feed supplements, adhesives, textile fibres, plastics, etc.) today announced its turnover figure for the first half of 2010.

In the first half of 2010 METabolic EXplorer recorded no "turnover".

For the record, the Company's turnover always virtually exclusively comprises license income for the two products (Glycolic Acid and L-Methionine) developed in partnership with manufacturer Roquette. In accordance with the development timetable for the two processes, which are currently in the preindustrial phase, no contract-based income was due in the first half of 2010.

### **Highlights**

### Sales activity: confidence in target for bringing products to market in 2012

The Company notes that it has rooted the validation of its business model in two separate development approaches, namely own-account development, and/or the set-up of a joint venture. These two approaches, developed in parallel, constitute the best means of maximizing shareholder value.

The sustained discussions which METabolic EXplorer has been carrying on around these two approaches, and notably concerning PDO, the first product to enter into the industrial pilot stage, mean that the Company is confident that it can achieve the target announced when it first obtained its stock-market listing, namely to bring the first products derived from METEX technology to market in 2012.

### Infrastructure: extension of R&D laboratories

As the last stage in the major investment programme designed to optimize company infrastructure, work on extending the R&D laboratories and administrative premises was completed in June this year. The new premises take METabolic EXplorer's property portfolio to 4,200m2, furnishing it with a unique asset offering a comprehensive capability from research to mass-production.

The company has now reached a size tailored to its self-imposed targets, in terms both of its infrastructure and workforce (113 staff).

# Partnerships: sharing the scientific innovations of academic partners

In addition to its various scientific partnerships such as that with INSA, the French National Institute of Applied Science, signed in the framework of the Bio2Chem programme (see press release dated April 16<sup>th</sup>, 2010), METabolic EXplorer continues to develop partnerships designed to allow it to sustain a constant momentum of innovation that will ultimately create value for shareholders.

### Intellectual property: strengthened portfolio

At end-June 2010, METabolic EXplorer had an intellectual property portfolio comprising 299 patent applications in 50 families, including three new ones filed during the first six months of the year. The new patent families involve, respectively, Glycolic Acid, L-Methionine and 1,2 Propanediol (MPG).

#### **Financial situation**

As of June 30<sup>th</sup>, 2010, METabolic EXplorer, which is pursuing its usual strict management policy, had cash and equivalent of €43.8 million compared with €49.8 million as of December 31<sup>st</sup>, 2009.

-END-

# About METabolic EXplorer - www.metabolic-explorer.com

METabolic EXplorer is a biological chemistry company which was incorporated in 1999. Its goal is to help industrial businesses deal with the heralded "end of oil", so that they can continue to manufacture but in a sustainable way.

Based on the tried and tested principle of industrial fermentation, METabolic Explorer's solutions circumvent the problems posed by today's burdensome and expensive petrochemical processes via the use of a wide range of renewable, sustainable raw materials. By optimizing the metabolic yield of non-pathogenic bacteria in a contained, controlled environment, the company facilitates the production of chemical compounds used in a wide range of everyday goods (paints, solvents, adhesives and textile fibres) and industrial products (such as surgical thread and animal feed).

METabolic EXplorer is currently focusing its alternative biological solutions (implemented by the development of renewable, fermentation-based bioprocesses) on the production of five compounds that together have an estimated, annual, end-market value of €11 billion. The company's strategy will be implemented worldwide in two ways: either via limited-exclusivity industrial partnerships, or via the creation of manufacturing facilities at METabolic EXplorer's own initiative.

METabolic Explorer, based in Clermont-Ferrand, France, is listed on EURONEXT PARIS (EURONEXT C, METEX) and features in the SBF 250 and CAC Small 90 indexes.

Get free financial information on METabolic EXplorer by registering with www.metabolic-explorer.com or www.actus-finance.com.

### **METabolic Explorer contacts**

### Media and shareholder contacts

# **ATTITUDE Corporate**

Eric de Lambert

E-mail: <a href="mailto:edelambert@attitude-corporate.com">edelambert@attitude-corporate.com</a>
Tel.: +33 (0)1 4970 4341 / +33 (0)6 2529 0658

Emmanuelle Lapeyre

E-mail: <u>elapeyre@attitude-corporate.com</u> Tel.: +33 (0)1 4970 4343 / +33 (0)6 1588 6209

Investor and analyst contacts

**Actus Finance** 

Jérôme Fabreguettes-Leib E-mail: jfl@actus.fr

Tel.: +33 (0)1 7735 0436

This communication includes forward-looking information which is subject to risks and uncertainties. The potential development of the company could be substantially different from that anticipated in this press release because of the various risk factors which are described in the company's Listing Prospectus.